Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)-Reference-Cited by-同舟云学术

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)

Published:2016-11-17 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Singh Jasvinder A¹,Hossain Alomgir²,Tanjong Ghogomu Elizabeth³,Mudano Amy S⁴,Tugwell Peter⁵,Wells George A⁶

Affiliation:

1. Birmingham VA Medical Center; Department of Medicine; Faculty Office Tower 805B 510 20th Street South Birmingham AL USA 35294

2. University of Ottawa Heart Institute; Cardiovascular Research Methods Centre; 40 Ruskin Street Room H-2265 Ottawa ON Canada K1Y 4W7

3. University of Ottawa; Bruyère Research Institute; 43 Bruyère St Annex E, room 302 Ottawa ON Canada K1N 5C8

4. University of Alabama at Birmingham; Department of Medicine - Rheumatology; Birmingham USA

5. Faculty of Medicine, University of Ottawa; Department of Medicine; Ottawa ON Canada K1H 8M5

6. University of Ottawa; Department of Epidemiology and Community Medicine; Room H1281 40 Ruskin Street Ottawa ON Canada K1Y 4W7

Publisher

Wiley

Subject

Pharmacology (medical)

Reference304 articles.

1. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis;Boyle;Ann Rheum Dis,2015

2. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist;Bresnihan;Arthritis Rheum,1998

3. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study);Burmester;Ann Rheum Dis,2014

4. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study;Combe;Ann Rheum Dis,2009

5. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial;Coombs;Ann Rheum Dis,2010

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation Program;Value in Health;2024-08

2. The Effect of Depression on Disease Activity and Treatment Response in Patients with Inflammatory Arthritis: Results from a Narrative Literature Review;Neuropsychiatric Disease and Treatment;2024-07

3. Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy;Frontiers in Immunology;2024-06-24

4. Twenty years of network meta‐analysis: Continuing controversies and recent developments;Research Synthesis Methods;2024-01-18

5. Therapeutic advances in rheumatoid arthritis;BMJ;2024-01-17